HCA Healthcare, Inc. (HCA)

FairStock Score: 69/100 — STEADY

Key Financials

Strengths

• Exceptional free cash flow generation of $5.8B annually enables debt reduction and shareholder returns
• Piotroski F-Score of 8/9 demonstrates strong financial reporting quality and operational discipline
• Diversified healthcare ecosystem spanning hospitals, ASCs, urgent care, and ancillary services reduces revenue concentration
• Q4 2025 net margin of 9.62% shows pricing power and operational efficiency in a competitive industry
• Market leadership position with 230,000 employees provides scale and negotiating leverage with payers

Concerns

• Valuation is stretched at 40.81x EV/EBITDA and 17.4x P/E with minimal margin of safety for downside protection
• Altman Z-Score of 1.50 signals heightened financial distress risk, concerning for a leveraged healthcare operator
• Return on Capital Employed of 12.44% barely exceeds cost of capital, indicating modest competitive advantages despite scale
• FCF yield of 0.7% is inadequate compensation for equity risk in a capital-intensive, regulated industry facing wage inflation

AI Analysis

HCA Healthcare presents a classic case of a mature, cash-generative business trading at a premium valuation. With $5.8B in free cash flow and a 9.62% net margin, the company demonstrates operational excellence in managing 230,000 employees across a diversified healthcare ecosystem. The Piotroski F-Score of 8/9 indicates solid financial quality and disciplined management. However, I must apply Graham's margin of safety principle here, and the numbers give me pause. At 17.4x earnings with an EV/EBITDA of 40.81x, we're paying dearly for growth that isn't evident in the disclosed metrics. The ROCE of 12.44% is respectable but unspectacular—barely above cost of capital—suggesting limited competitive moat despite market dominance. The FCF yield of just 0.7% is anemic for a capital-intensive healthcare operator. Most concerning is the Altman Z-Score of 1.50, indicating moderate financial distress risk. This isn't a business I'd buy near all-time highs. The secular tailwinds from aging demographics are real, but they're already priced in. I'd want to see this stock at $350-380 before reconsidering—a 30% discount to provide adequate margin of safety. Until then, the risk-reward is unfavorable for value-oriented investors.

Bull Case

Demographic tailwinds from an aging population will drive decades of healthcare demand growth, and HCA's operational expertise and scale position it to capture disproportionate share. The company's consistent FCF generation and proven ability to refinance debt provides optionality for M&A, share buybacks, and dividend growth in an inflationary environment.

Bear Case

Healthcare cost pressures, labor inflation, and potential regulatory headwinds could compress already modest returns on capital. Rising interest rates increase refinancing risk given the company's leverage profile, while the stretched valuation leaves zero room for execution missteps or cyclical slowdowns.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer